Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mood and Anxiety Research, Inc
• Treatments: Selegiline

Criteria

Inclusion Criteria:

• Subject has primary diagnosis of Borderline Personality Disorder(BPD).

• Subject has Symptomatology of BPD for at least 1 year.

• Subject understands the study procedures and voluntarily agree to participate.

• Subject is able to read, understand and complete questionnaires.

• Subject agrees to use (2)acceptable forms of contraception throughout the study.

• Patient must have a screening SCL 90-R score of > 120 (range 0-360).

Exclusion Criteria:

• Subject is not pregnant or breast feeding.

• Subject is unlikely to adhere to the study procedures and restrictions.

• Patient has failed treatment due to lack of efficacy of monoamine oxidase inhibitor(MAOI) medication.

• Patient anticipates need for surgery during the study.

• Patient has another predominant personality disorder other than BPD.

• Subject has an active history of substance abuse or dependence, e.g.,Positive Drug screen

• Subject has other health issues which could interfere with study interpretation.

• Subject reports recent suicide attempts or homicide attempts in the past 3 months.

• Subject must be substance abuse or dependence clean for (1) year.

• Subject has a history of a primary malignancy < 5 yrs.

• Subject has a medical condition(s)that are excluded, per Protocol, or are unstable.

• Subject has abnormal screening laboratory values, per Protocol, or other clinically significant, unexplained laboratory abnormality.

• Subject is currently participating or has participated in a study within 30 days.

• Patient has donated blood products or has had phlebotomy of > 300 ml within 8 weeks.